HUE050485T2 - Tauopathia kezelési módszerei - Google Patents

Tauopathia kezelési módszerei

Info

Publication number
HUE050485T2
HUE050485T2 HUE14734364A HUE14734364A HUE050485T2 HU E050485 T2 HUE050485 T2 HU E050485T2 HU E14734364 A HUE14734364 A HU E14734364A HU E14734364 A HUE14734364 A HU E14734364A HU E050485 T2 HUE050485 T2 HU E050485T2
Authority
HU
Hungary
Prior art keywords
tauopathy
treating
methods
Prior art date
Application number
HUE14734364A
Other languages
English (en)
Inventor
Irene Griswold-Prenner
Nancy Stagliano
Vu Cao Dang
Sami Hussain
Jessica Bright
Original Assignee
Ipierian Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2013/055203 external-priority patent/WO2014028777A2/en
Application filed by Ipierian Inc filed Critical Ipierian Inc
Publication of HUE050485T2 publication Critical patent/HUE050485T2/hu

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
HUE14734364A 2013-06-10 2014-06-09 Tauopathia kezelési módszerei HUE050485T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361833355P 2013-06-10 2013-06-10
PCT/US2013/055203 WO2014028777A2 (en) 2012-08-16 2013-08-15 Methods of treating a tauopathy
US14/092,539 US8926974B2 (en) 2012-08-16 2013-11-27 Methods of treating a tauopathy

Publications (1)

Publication Number Publication Date
HUE050485T2 true HUE050485T2 (hu) 2020-12-28

Family

ID=52022687

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14734364A HUE050485T2 (hu) 2013-06-10 2014-06-09 Tauopathia kezelési módszerei

Country Status (18)

Country Link
EP (2) EP3760228A1 (hu)
JP (1) JP6446443B2 (hu)
CN (1) CN105339002B (hu)
BR (1) BR112015030356A2 (hu)
CA (2) CA3173775A1 (hu)
CY (1) CY1123672T1 (hu)
DK (1) DK3007726T3 (hu)
EA (1) EA039554B1 (hu)
ES (1) ES2800827T3 (hu)
HR (1) HRP20201064T1 (hu)
HU (1) HUE050485T2 (hu)
LT (1) LT3007726T (hu)
MX (2) MX370723B (hu)
PL (1) PL3007726T3 (hu)
PT (1) PT3007726T (hu)
RS (1) RS60883B1 (hu)
SI (1) SI3007726T1 (hu)
WO (1) WO2014200921A1 (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ730763A (en) 2012-08-16 2018-06-29 Ipierian Inc Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
NZ630610A (en) 2014-02-14 2019-05-31 Ipierian Inc Tau peptides, anti-tau antibodies, and methods of use thereof
AR103713A1 (es) 2015-02-26 2017-05-31 Lilly Co Eli Anticuerpos contra tau y sus usos
CN107849124B (zh) * 2015-06-05 2021-09-24 基因泰克公司 抗tau抗体及使用方法
WO2018031361A2 (en) 2016-08-09 2018-02-15 Eli Lilly And Company Combination therapy
FR3058143B1 (fr) * 2016-10-27 2021-03-12 Univ Grenoble Alpes Nanocorps anti-tau
WO2018106781A1 (en) * 2016-12-07 2018-06-14 Genentech, Inc Anti-tau antibodies and methods of use
KR20240035636A (ko) 2016-12-07 2024-03-15 제넨테크, 인크. 항-타우 항체 및 이의 이용 방법
JOP20180014A1 (ar) 2017-02-27 2019-01-30 Teijin Pharma Ltd جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه
MX2019015071A (es) * 2017-06-16 2020-02-13 Bristol Myers Squibb Co Composiciones y metodos para tratar tauopatias.
PE20210115A1 (es) 2017-10-16 2021-01-19 Eisai Randd Man Co Ltd Anticuerpos anti-tau y uso de los mismos
WO2020028141A1 (en) 2018-07-31 2020-02-06 Eli Lilly And Company Combination therapy
JP2022043373A (ja) * 2018-12-28 2022-03-16 国立大学法人京都大学 大脳皮質細胞からのl1cam陽性細胞の取得およびその細胞製剤としての使用
US20220177558A1 (en) * 2019-03-25 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of taupathy disorders by targeting new tau species

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4866132A (en) 1986-04-17 1989-09-12 The Research Foundation Of State University Of New York Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5811310A (en) * 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
EP0623679B1 (en) 1987-05-21 2003-06-25 Micromet AG Targeted multifunctional proteins
US5256334A (en) 1988-09-08 1993-10-26 The Research Foundation Of The State University Of New York Homogeneous radiopaque polymer-organobismuth composites
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DK0648271T3 (da) 1991-08-20 2003-07-21 Us Gov Health & Human Serv Adenovirusmedieret overførsel af gener til mave-/tarmkanal
DE69229477T2 (de) 1991-09-23 1999-12-09 Cambridge Antibody Tech Methoden zur Herstellung humanisierter Antikörper
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
CA2145641C (en) 1992-12-03 2008-05-27 Richard J. Gregory Pseudo-adenovirus vectors
US6010913A (en) 1992-12-14 2000-01-04 N.V. Innogenetics S.A. Isolated human tau peptide
US5346981A (en) 1993-01-13 1994-09-13 Miles Inc. Radiopaque polyurethanes
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
DE69434486T2 (de) 1993-06-24 2006-07-06 Advec Inc. Adenovirus vektoren für gentherapie
ATE437232T1 (de) 1993-10-25 2009-08-15 Canji Inc Rekombinanter adenoviren-vektor und verfahren zur verwendung
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
DE69526377T2 (de) 1994-12-09 2002-11-07 Microscience Ltd Virulenzgene in der VGC2-Region von Salmonella
US5939045A (en) 1994-12-22 1999-08-17 Nissan Chemical Industries, Ltd. Organic bismuth derivatives for X-ray imaging
US5958713A (en) 1995-01-31 1999-09-28 Novo Nordisk A/S Method of detecting biologically active substances by using green fluorescent protein
US5670477A (en) 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
US5968738A (en) 1995-12-06 1999-10-19 The Board Of Trustees Of The Leland Stanford Junior University Two-reporter FACS analysis of mammalian cells using green fluorescent proteins
US6020192A (en) 1996-01-18 2000-02-01 University Of Florida Humanized green fluorescent protein genes and methods
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
JP4162267B2 (ja) 1996-08-27 2008-10-08 カイロン コーポレイション Neisseria meningitidis血清型B複合糖質およびその使用法
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
TW371617B (en) 1996-10-09 1999-10-11 Of Animal And Plant Health Inspection And Quarantine Council Of Agriculture Executive Yuan Bureau Method to transplant GFP into autographa californica multiple nuclear polyhedrosis virus for inflicting pest in an attempt to detect and flow up it existence and to improve life span against UV
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
JP2001525470A (ja) 1997-12-12 2001-12-11 マクロメド・インコーポレーテッド タンパク修飾のためのヘテロ官能化星形ポリ(エチレングリコール)
US5985577A (en) 1998-10-14 1999-11-16 The Trustees Of Columbia University In The City Of New York Protein conjugates containing multimers of green fluorescent protein
ATE342509T1 (de) 2000-01-24 2006-11-15 Innogenetics Nv Diagnose von tauopathien durch bestimmung des verhältnisses von tau/phospho-tau
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
GB0117326D0 (en) 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
DK1427709T3 (da) 2001-09-21 2006-04-03 Mitsubishi Pharma Corp 3-substituerede 4-pyrimidonderivater
NZ551335A (en) 2004-06-18 2010-03-26 Ambrx Inc Antibodies and fragments thereof comprising an non naturally encoded amino acid coupled to a linker
US20090016959A1 (en) 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
CN102348723A (zh) 2008-12-05 2012-02-08 安吉奥开米公司 肽治疗剂轭合物及其应用
US9605054B2 (en) * 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
EP2627672B1 (en) * 2010-10-11 2018-08-01 Biogen Idec International Neuroscience GmbH Human anti-tau antibodies
ES2714692T3 (es) * 2011-01-31 2019-05-29 Tau Bio Logic Corp Tratamiento de tauopatías
GB201112056D0 (en) * 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
NZ730763A (en) * 2012-08-16 2018-06-29 Ipierian Inc Methods of treating a tauopathy
US20140056901A1 (en) * 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies

Also Published As

Publication number Publication date
SI3007726T1 (sl) 2020-11-30
MX2019015604A (es) 2020-02-26
LT3007726T (lt) 2020-09-10
PT3007726T (pt) 2020-06-22
EA039554B1 (ru) 2022-02-09
JP6446443B2 (ja) 2018-12-26
ES2800827T3 (es) 2021-01-04
CA3173775A1 (en) 2014-12-18
CY1123672T1 (el) 2022-03-24
MX370723B (es) 2019-12-20
HRP20201064T1 (hr) 2021-01-22
EP3007726A1 (en) 2016-04-20
CN105339002B (zh) 2019-06-28
EP3760228A1 (en) 2021-01-06
BR112015030356A2 (pt) 2017-12-05
WO2014200921A1 (en) 2014-12-18
DK3007726T3 (da) 2020-07-06
EP3007726B1 (en) 2020-04-08
PL3007726T3 (pl) 2021-01-11
EA201592203A1 (ru) 2016-05-31
CN105339002A (zh) 2016-02-17
MX2015016240A (es) 2016-08-11
JP2016525502A (ja) 2016-08-25
CA2914768A1 (en) 2014-12-18
RS60883B1 (sr) 2020-11-30

Similar Documents

Publication Publication Date Title
IL237153A0 (en) Methods of therapeutic treatment
PL3007726T3 (pl) Metody leczenia tauopatii
EP2945639A4 (en) METHOD FOR THE TREATMENT OF HEART DISEASES
SG11201508447TA (en) Expression process
HK1215164A1 (zh) 處理方法
GB201304872D0 (en) Treatment
IL241096B (en) Treatment methods
GB201302441D0 (en) Process
GB201415000D0 (en) Improved process
GB201322992D0 (en) New Process
GB201316901D0 (en) Method of treating a borehole
GB201300073D0 (en) Process
GB201317756D0 (en) New process
GB201313211D0 (en) New process
GB201307310D0 (en) Treatment
PL3041506T3 (pl) Sposób leczenia
GB201322778D0 (en) Method of treatment
GB201314882D0 (en) Method of treatment
GB201321442D0 (en) Expression process
GB201320339D0 (en) Expression Process
GB201319930D0 (en) Expression process
GB201321115D0 (en) Treatment
GB201311837D0 (en) Expression Process
GB201308017D0 (en) Expression process
GB201309238D0 (en) Treatment